tetracosactide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| synthetic polypeptides with a corticotropin-like action | 4516 | 16960-16-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.25 | mg | P |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 22, 1970 | FDA | AMPHASTAR PHARMS INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adrenal haematoma | 49.25 | 43.20 | 5 | 54 | 55 | 34956817 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Adrenal haematoma | 43.04 | 37.16 | 5 | 175 | 146 | 79744062 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H01AA02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ACTH |
| FDA CS | M0000499 | Adrenocorticotropic Hormone |
| CHEBI has role | CHEBI:33295 | diagnostic aid |
| MeSH PA | D006728 | Hormones |
| FDA EPC | N0000175941 | Adrenocorticotropic Hormone |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Cosyntropin preparation | indication | 126188005 | |
| Adrenal cortical hypofunction | indication | 386584007 | DOID:10493 |
| Diagnostic Test for Secondary Adrenocortical Insufficiency | indication | ||
| West syndrome | off-label use | 28055006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.35 | acidic |
| pKa2 | 4.08 | acidic |
| pKa3 | 9.43 | acidic |
| pKa4 | 10.05 | acidic |
| pKa5 | 12.36 | acidic |
| pKa6 | 12.72 | acidic |
| pKa7 | 13.1 | acidic |
| pKa8 | 13.34 | acidic |
| pKa9 | 13.43 | acidic |
| pKa10 | 13.64 | acidic |
| pKa11 | 13.82 | acidic |
| pKa12 | 13.87 | acidic |
| pKa13 | 11.5 | Basic |
| pKa14 | 11.26 | Basic |
| pKa15 | 11.01 | Basic |
| pKa16 | 10.81 | Basic |
| pKa17 | 10.55 | Basic |
| pKa18 | 10.3 | Basic |
| pKa19 | 9.94 | Basic |
| pKa20 | 7.62 | Basic |
| pKa21 | 6.69 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Adrenocorticotropic hormone receptor | GPCR | AGONIST | Ki | 8.27 | SCIENTIFIC LITERATURE | CHEMBL | |||
| Melanocortin receptor 4 | GPCR | EC50 | 9.19 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00284 | KEGG_DRUG |
| 4018522 | VUID |
| N0000146844 | NUI |
| 4018522 | VANDF |
| CHEBI:3901 | CHEBI |
| CHEMBL2103784 | ChEMBL_ID |
| 6965 | IUPHAR_LIGAND_ID |
| DB01284 | DRUGBANK_ID |
| 2890 | RXNORM |
| 132939 | MMSL |
| 4509 | MMSL |
| d00607 | MMSL |
| 002115 | NDDF |
| 005142 | NDDF |
| 325824002 | SNOMEDCT_US |
| 425646006 | SNOMEDCT_US |
| 96363002 | SNOMEDCT_US |
| C0010192 | UMLSCUI |
| D003366 | MESH_DESCRIPTOR_UI |
| 2255 | INN_ID |
| 16133802 | PUBCHEM_CID |
| 72YY86EA29 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cortrosyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9839 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | PARENTERAL | NDA | 10 sections |
| Cortrosyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9839 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | PARENTERAL | NDA | 10 sections |
| Cortrosyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-5900 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | INTRAMUSCULAR | NDA | 17 sections |
| Cortrosyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-5900 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | INTRAMUSCULAR | NDA | 17 sections |
| Cosyntropin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3440 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | INTRAVENOUS | ANDA | 16 sections |
| Cortrosyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4547 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | INTRAMUSCULAR | NDA | 16 sections |
| COSYNTROPIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1567 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | INTRAVENOUS | ANDA | 10 sections |
| Cortrosyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-050 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 mg | PARENTERAL | NDA | 10 sections |
| Cosyntropin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-227 | INJECTION, POWDER, FOR SOLUTION | 0.25 mg | INTRAVENOUS | ANDA | 16 sections |
| Cosyntropin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-227 | INJECTION, POWDER, FOR SOLUTION | 0.25 mg | INTRAVENOUS | ANDA | 16 sections |